D
Madrigal Pharmaceuticals, Inc. MDGL
$579.89 $6.741.18% NASDAQ
Recommendation
Prev Close
$573.15
Volume
264,526
Avg Vol (90D)
375,539
Market Cap
$13.02B
Dividend & Yield
--
52-Week Range
$265.00 - $605.00
P/E (TTM)
--
EPS (TTM)
-$13.01
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
MarketBeat Week in Review – 09/08 - 09/12
9/13/2025 - MarketBeat
Russell Investments Group Ltd. Increases Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
12/3/2025 - MarketBeat
A Fresh Look at Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Launch and Pipeline Progress
12/2/2025 - Simply Wall St
Madrigal Pharmaceuticals (MDGL, $579.45) RSI Indicator left the overbought zone on December 01, 2025
12/2/2025 - Tickeron - Stocks
Two Sector ETFs Are Quietly Outperforming the S&P 500 Without a Single AI Stock
12/2/2025 - 24/7 Wall St.
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug
12/1/2025 - Yahoo! Finance: News
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug
12/1/2025 - Insider Monkey
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Franklin Resources Inc.
11/30/2025 - MarketBeat
Groupama Asset Managment Purchases 7,439 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
11/29/2025 - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by American Century Companies Inc.
11/29/2025 - MarketBeat
Why Madrigal Pharmaceuticals (MDGL) Is Up 8.9% After Positive Two-Year Rezdiffra Data in MASH Cirrhosis
11/28/2025 - Simply Wall St
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
11/28/2025 - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts
11/28/2025 - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 12-Month High on Analyst Upgrade
11/25/2025 - MarketBeat
Madrigal Pharmaceuticals (MDGL, $587.92) RSI Indicator left the overbought zone on November 24, 2025
11/25/2025 - Tickeron - Stocks
Magnetar Financial LLC Makes New $2.04 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL
11/24/2025 - MarketBeat
A Look at Madrigal Pharmaceuticals's Valuation Following Positive Phase 3 Rezdiffra Results for MASH Cirrhosis
11/23/2025 - Simply Wall St
Carole Huntsman Sells 1,958 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
11/23/2025 - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given New $620.00 Price Target at HC Wainwright
11/22/2025 - MarketBeat
Carole Huntsman Sells 1,958 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
11/22/2025 - MarketBeat
Carole Huntsman Sells 1,958 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
11/22/2025 - Zolmax
Madrigal Pharmaceuticals (MDGL) Sees Analyst Upgrade with Target Price Raised to $620 MDGL ...
11/21/2025 - GuruFocus
Madrigal price target raised to $620 from $568 at H.C. Wainwright
11/21/2025 - TipRanks Financial Blog
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $650.00
11/21/2025 - MarketBeat
CoreWeave and Madrigal's Insider Trades Flash Bullish Signals
9/10/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$740.64M
EBITDA (TTM)
-$306.01M
EBIT (TTM)
-$307.48M
Net Income (TTM)
-$289.13M
Balance Sheet
Total Assets (Q)
$1.36B
Total Debt (Q)
$346.40M
Total Liabilities (Q)
$736.73M
Book Value Per Share (Q)
$27.56
Cash Flow
Cash from Operations (TTM)
-$160.58M
Cash from Investing (TTM)
-$43.21M
Cash from Financing (TTM)
$266.80M
Net Change in Cash (TTM)
$63.01M
Filings
Filing Date
Tuesday, November 4, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
0.74
7-Day Total Return
5.83%
30-Day Total Return
34.86%
60-Day Total Return
29.23%
90-Day Total Return
97.13%
Year to Date Total Return
84.81%
1-Year Total Return
80.45%
2-Year Total Return
161.24%
3-Year Total Return
695.79%
5-Year Total Return
390.06%
52-week Low
May 27, 2025 - $265.00
52-week High
Nov 28, 2025 - $605.00
Valuation
Market Cap
$13.02B - Large Cap
Enterprise Value
$12.25B
Price/Sales (TTM)
17.40
Price/Book (Q)
20.80
Dividends and Shares
Shares Outstanding
22.48
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.madrigalpharma.com
Phone Number
267 824 2827
Address
Four Tower Bridge
Suite 200 - 200 Barr Harbor Drive
West Conshohocken, PA 19428
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed